HRP20241653T1 - Uporaba sepiapterina i njegovih metabolita za liječenje izloženosti zračenju - Google Patents

Uporaba sepiapterina i njegovih metabolita za liječenje izloženosti zračenju Download PDF

Info

Publication number
HRP20241653T1
HRP20241653T1 HRP20241653TT HRP20241653T HRP20241653T1 HR P20241653 T1 HRP20241653 T1 HR P20241653T1 HR P20241653T T HRP20241653T T HR P20241653TT HR P20241653 T HRP20241653 T HR P20241653T HR P20241653 T1 HRP20241653 T1 HR P20241653T1
Authority
HR
Croatia
Prior art keywords
sepiapterin
cocrystal
mir
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
HRP20241653TT
Other languages
English (en)
Croatian (hr)
Inventor
Eleonora MEZZAROMA
Christopher RABENDER
Ross MIKKELSEN
Vasily YAKOVLEV
Niel SMITH
Original Assignee
Ptc Therapeutics Mp, Inc.
Virginia Commonwealth University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics Mp, Inc., Virginia Commonwealth University filed Critical Ptc Therapeutics Mp, Inc.
Publication of HRP20241653T1 publication Critical patent/HRP20241653T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
HRP20241653TT 2019-08-05 2020-08-05 Uporaba sepiapterina i njegovih metabolita za liječenje izloženosti zračenju HRP20241653T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962882937P 2019-08-05 2019-08-05
PCT/US2020/045026 WO2021026247A1 (en) 2019-08-05 2020-08-05 Use of sepiapterin and metabolites thereof to treat radiation exposure
EP20758407.9A EP4009978B1 (en) 2019-08-05 2020-08-05 Use of sepiapterin and metabolites thereof to treat radiation exposure

Publications (1)

Publication Number Publication Date
HRP20241653T1 true HRP20241653T1 (hr) 2025-04-25

Family

ID=72148243

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20241653TT HRP20241653T1 (hr) 2019-08-05 2020-08-05 Uporaba sepiapterina i njegovih metabolita za liječenje izloženosti zračenju

Country Status (21)

Country Link
US (1) US12667569B2 (cg-RX-API-DMAC10.html)
EP (2) EP4454712A3 (cg-RX-API-DMAC10.html)
JP (2) JP7642611B2 (cg-RX-API-DMAC10.html)
CN (2) CN119837879A (cg-RX-API-DMAC10.html)
AU (1) AU2020324435B2 (cg-RX-API-DMAC10.html)
BR (1) BR112022002029A2 (cg-RX-API-DMAC10.html)
CA (1) CA3146477A1 (cg-RX-API-DMAC10.html)
DK (1) DK4009978T3 (cg-RX-API-DMAC10.html)
ES (1) ES2994060T3 (cg-RX-API-DMAC10.html)
FI (1) FI4009978T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20241653T1 (cg-RX-API-DMAC10.html)
HU (1) HUE069012T2 (cg-RX-API-DMAC10.html)
IL (1) IL290321B2 (cg-RX-API-DMAC10.html)
LT (1) LT4009978T (cg-RX-API-DMAC10.html)
MX (1) MX2022001535A (cg-RX-API-DMAC10.html)
PL (1) PL4009978T3 (cg-RX-API-DMAC10.html)
PT (1) PT4009978T (cg-RX-API-DMAC10.html)
RS (1) RS66096B1 (cg-RX-API-DMAC10.html)
SI (1) SI4009978T1 (cg-RX-API-DMAC10.html)
SM (1) SMT202500089T1 (cg-RX-API-DMAC10.html)
WO (1) WO2021026247A1 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110312721A (zh) 2016-11-29 2019-10-08 显莎制药公司 墨蝶呤的多晶型物
WO2018102315A1 (en) 2016-11-29 2018-06-07 Censa Pharmaceuticals Inc. Polymoprhs of sepiapterin and salts thereof
MX2020002271A (es) 2017-09-01 2020-10-05 Ptc Therapeutics Mp Inc Composiciones farmaceuticas que comprenden sepiapterina y sus usos de las mismas.
CA3102105A1 (en) 2018-05-30 2019-12-05 Ptc Therapeutics Mp, Inc. Compositions and methods for increasing tetrahydrobiopterin plasma exposure
JP7778477B2 (ja) 2018-05-30 2025-12-02 ピーティーシー セラピューティクス エムピー,インコーポレイテッド セピアプテリンの薬学的に許容される塩
JP7502197B2 (ja) 2018-05-30 2024-06-18 ピーティーシー セラピューティクス エムピー,インコーポレイテッド セピアプテリン血漿曝露を増加させるための方法
LT4009978T (lt) 2019-08-05 2024-11-25 Ptc Therapeutics Mp, Inc. Sepiapterino ir jo metabolitų panaudojimas spinduliuotės poveikio gydymui
US12691119B2 (en) 2021-02-09 2026-07-28 Ptc Therapeutics Mp, Inc. Methods for treating covid-19 with sepiapterin

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5925323A (ja) 1982-03-03 1984-02-09 鐘淵化学工業株式会社 プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤
US5910304A (en) 1982-12-13 1999-06-08 Texas A&M University System Low-dose oral administration of interferons
CA1320905C (en) 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
US6036949A (en) 1998-03-05 2000-03-14 Amarillo Biosciences, Inc. Treatment of fibromyalgia with low doses of interferon
US8188043B2 (en) 1999-07-28 2012-05-29 The Board Of Trustees Of The Leland Stanford Jr. University Nicotine in therapeutic angiogenesis and vasculogenesis
WO2005048926A2 (en) * 2003-11-13 2005-06-02 The General Hospital Corporation Methods for treating pain
PT3138566T (pt) 2003-11-17 2022-02-02 Biomarin Pharm Inc Tratamento de fenilcetonúria com bh4
CA2545968C (en) 2003-11-17 2010-03-09 Merck Eprova Ag Crystalline forms of (6r)-l-erythro-tetrahydrobiopterin dihydrochloride
JP5184783B2 (ja) 2003-11-17 2013-04-17 バイオマリン ファーマシューティカル インコーポレイテッド テトラヒドロビオプテリン、及びテトラヒドロビオプテリン類似体の製造方法
CN101132776A (zh) 2004-11-17 2008-02-27 生物马林药物股份有限公司 稳定的四氢生物喋呤片剂制剂
US20100130500A1 (en) 2004-12-08 2010-05-27 Biomarin Pharmaceutical Inc. Methods and compositions for the treatment of pulmonary hypertension of the newborn
WO2006118322A1 (en) 2005-04-28 2006-11-09 Shiratori Pharmaceutical Co., Ltd. Method for producing hydrazone derivatives
TWI359019B (en) * 2006-08-14 2012-03-01 Merck Eprova Ag Use of folates for the prevention and treatment of
US20080075666A1 (en) 2006-08-25 2008-03-27 Dudley Samuel C Jr Methods and compositions for treating diastolic dysfunction
KR20160065998A (ko) 2007-04-11 2016-06-09 바이오마린 파머수티컬 인크. 테트라하이드로바이오프테린 투여 방법, 관련 조성물 및 측정 방법
WO2010017570A2 (de) 2008-08-12 2010-02-18 Orpha Swiss Gmbh Pharmazeutische darreichungsform enthaltend tetrahydrobiopterin
JP5066756B2 (ja) 2010-04-22 2012-11-07 学校法人日本大学 脳機能障害予防・改善用の薬剤及び飲食物
CA2828685C (en) 2011-03-01 2018-05-29 Rubicon Research Private Limited Stable compositions of tetrahydrobiopterin
US9216178B2 (en) 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
JP6084967B2 (ja) 2012-05-07 2017-02-22 白鳥製薬株式会社 セピアプテリン及びテトラヒドロラクトイルプテリンの製造法
JP2016530333A (ja) * 2013-09-13 2016-09-29 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー 放射線の影響から防護するため及び放射線の影響を緩和するための組成物の調製及び使用
CN114306208A (zh) * 2014-10-02 2022-04-12 西托索尔本茨公司 经胃肠施用的多孔消化道吸着剂聚合物用于预防或治疗的用途
WO2018019931A1 (en) 2016-07-29 2018-02-01 Dipharma S.A. Pharmaceutical composition kit comprising sapropterin dihydrochloride
WO2018102315A1 (en) 2016-11-29 2018-06-07 Censa Pharmaceuticals Inc. Polymoprhs of sepiapterin and salts thereof
CN110312721A (zh) 2016-11-29 2019-10-08 显莎制药公司 墨蝶呤的多晶型物
MX2020002271A (es) 2017-09-01 2020-10-05 Ptc Therapeutics Mp Inc Composiciones farmaceuticas que comprenden sepiapterina y sus usos de las mismas.
JP7778477B2 (ja) 2018-05-30 2025-12-02 ピーティーシー セラピューティクス エムピー,インコーポレイテッド セピアプテリンの薬学的に許容される塩
CA3102105A1 (en) 2018-05-30 2019-12-05 Ptc Therapeutics Mp, Inc. Compositions and methods for increasing tetrahydrobiopterin plasma exposure
JP7502197B2 (ja) 2018-05-30 2024-06-18 ピーティーシー セラピューティクス エムピー,インコーポレイテッド セピアプテリン血漿曝露を増加させるための方法
LT4009978T (lt) * 2019-08-05 2024-11-25 Ptc Therapeutics Mp, Inc. Sepiapterino ir jo metabolitų panaudojimas spinduliuotės poveikio gydymui
CN110354133A (zh) * 2019-08-26 2019-10-22 鞍山市肿瘤医院 四氢生物蝶呤的应用及药物
IL291565B1 (en) 2019-09-25 2026-04-01 Ptc Therapeutics Inc Method for treating phenylalanine irregularity
CA3165636A1 (en) 2020-01-24 2021-07-29 Neil Smith Methods for treating parkinson's disease with sepiapterin
IL305037A (en) 2021-02-09 2023-10-01 Ptc Therapeutics Mp Inc Methods of treating glioblastomas with spiafatrin
US12691119B2 (en) 2021-02-09 2026-07-28 Ptc Therapeutics Mp, Inc. Methods for treating covid-19 with sepiapterin
AR127191A1 (es) 2021-09-29 2023-12-27 Ptc Therapeutics Inc Composición farmacéutica de sepiapterina

Also Published As

Publication number Publication date
EP4009978A1 (en) 2022-06-15
EP4454712A2 (en) 2024-10-30
SMT202500089T1 (it) 2025-03-12
ES2994060T3 (en) 2025-01-16
CA3146477A1 (en) 2021-02-11
IL290321B2 (en) 2026-08-01
US12667569B2 (en) 2026-06-30
US20220273661A1 (en) 2022-09-01
EP4454712A3 (en) 2025-01-01
CN114555090A (zh) 2022-05-27
IL290321A (en) 2022-04-01
PT4009978T (pt) 2024-11-05
PL4009978T3 (pl) 2025-02-24
JP7642611B2 (ja) 2025-03-10
AU2020324435B2 (en) 2026-03-19
LT4009978T (lt) 2024-11-25
RS66096B1 (sr) 2024-11-29
JP2022543655A (ja) 2022-10-13
BR112022002029A2 (pt) 2022-06-07
FI4009978T3 (fi) 2024-11-01
IL290321B1 (en) 2026-04-01
CN119837879A (zh) 2025-04-18
EP4009978B1 (en) 2024-09-25
MX2022001535A (es) 2022-03-04
AU2020324435A1 (en) 2022-02-24
HUE069012T2 (hu) 2025-02-28
CN114555090B (zh) 2024-12-17
SI4009978T1 (sl) 2025-03-31
WO2021026247A1 (en) 2021-02-11
JP2025098011A (ja) 2025-07-01
DK4009978T3 (da) 2024-10-14

Similar Documents

Publication Publication Date Title
FI4009978T3 (fi) Sepiapteriiinin ja sen metaboliittien käyttö säteilyaltistuksen hoitoon
JP2022543655A5 (cg-RX-API-DMAC10.html)
Kma et al. Angiotensin converting enzyme inhibitors mitigate collagen synthesis induced by a single dose of radiation to the whole thorax
KR20100096108A (ko) 건성 점막 치료용 오스모라이트-함유 제제
JP2019517597A5 (cg-RX-API-DMAC10.html)
EP2249866A2 (de) Verwendung eines acetylsalicylsäuresalzes zur behandlung viraler infektionen
Popov et al. In vitro and in vivo evaluation of the efficacy and safety of powder hydroxypropylmethylcellulose as nasal mucosal barrier
WO2016193894A1 (en) Treatment of respiratory disorders using ror- gamma inhibitors
ES2272689T3 (es) Dihidro-triterpenos en el tratamiento de infecciones virales, enfermedad cardiovascular, inflamacion, hipersensibilidad o dolor.
RU2011138178A (ru) рН-МОДУЛИРОВАННЫЕ СОСТАВЫ ДЛЯ ДОСТАВКИ В ЛЕГКИЕ
TR201901516T4 (tr) Nöroprotektif ajanlar ve bunların kullanımları.
HRP20231209T1 (hr) Tekući pripravak za upotrebu u liječenju sluznice oro-faringo-laringo-ezofagealnog trakta
JP2008088189A5 (cg-RX-API-DMAC10.html)
JP2019535830A5 (cg-RX-API-DMAC10.html)
ES2987369T3 (es) Polímeros de acción doble en una película osmótica para administración tópica para tratar enfermedades inflamatorias y síndrome de liberación de citocinas
WO2022203546A1 (ru) Применение фосфолипидной эмульсии дигидрокверцетина при воспалительных заболеваниях органов дыхания
WO2021198220A1 (en) Treatment and prevention of secondary inflammation in patients suffering from a viral infection
CN100364975C (zh) 一种抗呼吸道病毒的药物及用途
WO2015131655A1 (zh) 佛司可林在防治慢性阻塞性肺病中的应用
CN105902534A (zh) 苯酚茶酸素在制备治疗或预防呼吸系统疾病药物中的应用
CN119770474B (zh) 9-羟基十五酸在制备防治肺损伤的药物中的应用
Arbak Effects of tear gases on the pulmonary system
WO2012004330A1 (de) Nos-inhibitor l-nil zur anwendung bei chronischen lungenerkrankungen
JP2002030000A (ja) 風邪根本治療法
CN119074852A (zh) 用于清肺利咽的中药组合物、药物制剂及用途